|
|
 Previous Article | Table of Contents | Next Article 
Differential expression of CD54/intercellular adhesion molecule-1 in
myeloid leukemias and in lymphoproliferative disorders
M Maio, A Pinto, A Carbone, V Zagonel, A Gloghini, G Marotta, D Cirillo, A Colombatti, F Ferrara and L Del Vecchio
Division of Experimental Oncology 2, CRO Aviano, Italy.
Indirect immunofluorescence staining with monoclonal antibody (MoAb)
CL203.4 of malignant cells from 269 patients with hematologic malignancies
showed a heterogeneous expression of CD54/intercellular adhesion molecule-1
(ICAM-1). This marker was expressed by malignant cells of 57 out of 118
patients with myeloid malignancies and 69 out of 135 with B-lymphoid
malignancies. On the other hand, CD54 was not detected on malignant cells
of 16 patients with T-lymphoid malignancies. In myeloid malignancies, CD54
is preferentially expressed by "stem cell-derived" malignancies, being
detectable on blast cells from almost all patients affected by chronic
myelogenous leukemia in blast phase or myelodysplastic syndromes and by
only 34% of patients with de novo acute myeloid leukemia (AML). The
expression of CD54 did not correlate with any specific myeloid FAB subtype,
although three cases of highly undifferentiated AML (FAB MO) displayed
maximal levels of the antigen. The expression of CD54 in AML was
significantly associated with that of CD34 and HLA-DR antigens. In
B-lymphoid malignancies, CD54 expression appears to correlate with the
differentiation stage of malignant cells, since B-origin acute
lymphoblastic leukemias and conventional B-chronic lymphocytic leukemias
(B-CLL; ie, "dim SIg" CLL) expressed lower levels of CD54 than more mature
lymphoproliferative disorders ("bright SIg" CLL, prolymphocytic leukemias,
and lymphoplasmacytic tumors). "High-grade" B- cell non-Hodgkin's lymphomas
(B-NHL) express in general a higher level of CD54 than "low-grade" ones.
This finding in conjunction with the expression of CD54 in all 17 patients
with "bright SIg" CLL investigated (characterized by marked organomegaly
and poor prognosis) suggest that the differential expression of CD54 in
lymphoproliferative disorders may also relate to their degree of
malignancy.
Volume 76,
Issue 4,
pp. 783-790,
08/15/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. P. Vallely, P. G. Bannon, C. F. Hughes, and L. Kritharides
Endothelial expression of intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 is suppressed by postbypass plasma containing increased soluble intercellular adhesion molecule 1 and vascular cell adhesion molecule 1
J. Thorac. Cardiovasc. Surg.,
October 1, 2002;
124(4):
758 - 767.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Braziel, D. A. Arber, M. L. Slovak, M. L. Gulley, C. Spier, C. Kjeldsberg, J. Unger, T. P. Miller, R. Tubbs, C. Leith, et al.
The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features
Blood,
June 15, 2001;
97(12):
3713 - 3720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Ohene-Abuakwa and M. Pignatelli
Adhesion Molecules as Diagnostic Tools in Tumor Pathology
International Journal of Surgical Pathology,
July 1, 2000;
8(3):
191 - 200.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. Fonsatti, A. P. Jekunen, K. J. A. Kairemo, S. Coral, M. Snellman, M. R. Nicotra, P. G. Natali, M. Altomonte, and M. Maio
Endoglin Is a Suitable Target for Efficient Imaging of Solid Tumors: In Vivo Evidence in a Canine Mammary Carcinoma Model
Clin. Cancer Res.,
May 1, 2000;
6(5):
2037 - 2043.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. Carrasco, P. Perez, A. Lewin, and R. Bravo
Ikappa Balpha Overexpression Delays Tumor Formation in v-rel Transgenic Mice
J. Exp. Med.,
July 21, 1997;
186(2):
279 - 288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Gattei, M. Degan, A. Gloghini, A. De Iuliis, S. Improta, F. M. Rossi, D. Aldinucci, V. Perin, D. Serraino, R. Babare, et al.
CD30 Ligand Is Frequently Expressed in Human Hematopoietic Malignancies of Myeloid and Lymphoid Origin
Blood,
March 15, 1997;
89(6):
2048 - 2059.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
